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Abstract
Systemic lupus erythematosus is characterized by antibodies to
a variety of intracellular self-antigens, such as dsDNA and Sm,
and these serve as hallmarks in the diagnosis of systemic
autoimmune diseases. Several studies have shown that SmD1
and SmD3 synthetic peptides represent highly functional
antigens for autoantibody detection and thus for diagnostic
applications. The present study analysed the technical and
clinical accuracy of an anti-SmD1 (amino acids 83–119) and an
anti-SmD3 (amino acids 108–122) ELISA for the detection of
anti-Sm antibodies. Depending on the cut-off value of the SmD1
ELISA, we found a high degree of concordance between the
two tests. At an optimized cut-off value of 100 units for SmD1
we found the same clinical sensitivity (12.5%) and specificity
(100%) in a group of systemic lupus erythematosus patients (n
= 48) and in controls (n = 99). The concordance at this cut-off
value was 100% (P < 0.0001; χ2 = 127.61). Using a second
panel of sera (n = 65) preselected based on positive anti-Sm
results, we confirmed the high degree of concordance between
the two assays. Using dsDNA-coated ELISA plates and
biotinylated peptides we confirmed the high dsDNA binding
properties for SmD1, which were significantly higher than the
SmD3-derived peptide. However, no cross-linking of anti-
dsDNA antibodies to SmD1 was observed after adding
increasing amounts of dsDNA to anti-dsDNA positive, anti-
SmD1 negative serum. We therefore conclude that the reported
difference in the sensitivity is related to the different cut-off levels
and not to the detection of anti-dsDNA antibodies bridged via
dsDNA to the SmD1 peptide. Moreover, we found that a
subpopulation of anti-Sm antibodies cross-reacted with SmD1
and SmD3. Taken together, the data indicate that both SmD
peptide ELISAs represent accurate assays and may be used as
important standards for the detection of anti-Sm antibodies.
Introduction
Systemic rheumatic diseases are characterized by circulating
autoantibodies to more than 200 autoantigens, which can pre-
cede the clinical onset of the disease and thus have high prog-
nostic value [1,2]. Among the earliest identified autoantibodies
were those directed to components of U2–U6 small nuclear
ribonucleoproteins (RNPs) known collectively as Sm, which
are highly specific for systemic lupus erythematosus (SLE) [3].
Anti-Sm antibodies have therefore been included as one of the
SLE classification criteria of the American College of Rheuma-
tology [4].
The Sm antigen is part of the spliceosomal complex that catal-
yses the splicing of nuclear pre-mRNA and is composed of at
least nine different polypeptides with molecular weights rang-
ing from 9 to 29.5 kDa (SmB1, SmB', SmB3, SmD1, SmD2,
SmD3, SmE, SmF and SmG) [5,6]. All of these core proteins,
but most frequently the SmB and SmD polypeptides, are tar-
gets of the anti-Sm autoimmune response [3]. Since SmBB'
and U1-specific RNPs share the cross-reactive epitope motif
PPPGMRPP, SmD is regarded as the most SLE-specific Sm
antigen [7]. Within the SmD autoantigen family, reactivity with
SmD1/D3 is at least four times more common than SmD1/
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SmD2/SmD3 recognition, with a pronounced immunoreactiv-
ity to SmD1 [8]. In epitope-mapping studies of SmD1 and
SmBB', the major reactivity was predominantly found in the C-
terminal regions [9-17]. Small nuclear RNPs such as SmD1,
SmD3, and SmBB' were recently shown to contain symmetri-
cal dimethylarginine (sDMA), and these modified residues
were shown to constitute major epitopes on the SmB and
SmD polypeptides [14,18].
Anti-Sm reactivity is found in 5–30% of patients with SLE, and
this frequency varies depending on the detection system, the
selection criteria for study cohorts and the ethnicity of the SLE
population under investigation [14-19]. Several immu-
noassays designed for research studies, as well as for diag-
nostic laboratory use, have been developed. The antigenic
analytes employed in these tests included purified native pro-
teins, recombinant polypeptides or synthetic peptides [14-
22]. In independent studies, a high degree of clinical accuracy
has been reported for SmD-derived peptide-based immu-
noassays (SmD183–119 and SmD3108–122) [14-16,20]. The
SmD1 peptide has been shown to be dependent on casein as
a cofactor for antibody binding, and the SmD3 peptide con-
tains an sDMA residue as a key amino acid [14,23].
The present study was designed to evaluate two SmD pep-
tide-based immunoassays and to analyse the putative effect of
dsDNA/SmD peptide complex formation on the diagnostic
accuracy of the SmD assays.
Materials and methods
Serum samples
A panel of sera (panel I) was collected from SLE patients (n =
48) and from patients with various control diseases including
rheumatoid arthritis (n = 50), mixed connective tissue disease
(MCTD) (n = 16), scleroderma (systemic sclerosis) (n = 17),
polymyositis/dermatomyositis (n = 11), and other autoimmune
disorders (n = 15). All samples were used in a previous study
and were classified according to published criteria for each
disease [16]. Sera were stored in aliquots at -80°C until use
and were shipped on dry ice. None of the samples had more
than two freezing and thawing cycles.
A second panel (panel II) of sera (n = 65) was selected based
on a positive anti-Sm test in the QUANTA Plex 8™ addressa-
ble laser bead immunoassay (see below). The international
antinuclear antibodies reference serum panel available from
the Centre of Disease Control and Prevention (CDC, Atlanta,
GA, USA) was also tested in the SmD peptide ELISAs [24].
Finally, a third panel of serum samples (panel III, n = 200) was
collected at the Charité – Universitätsmedizin (Berlin, Ger-
many), including samples from SLE patients (n = 100), from
patients with infectious diseases (malaria, hepatitis B virus,
hepatitis C virus, human immunodeficiency virus, five from
each group; n  = 20), from MCTD patients (n  = 7), from
CREST syndrome (calcinosis, Raynaud phenomenon,
oesophageal dysmotility, sclerodactyly, and telangiectasia)
patients (n = 8), from scleroderma patients (n = 10), from pol-
ymyositis patients (n = 6), from primary Sjögren's syndrome
patients (n = 7), from rheumatoid arthritis patients (n = 22)
and from normal controls (n = 20). The samples were used to
validate the newly defined cut-off value of the SmD1 ELISA.
Synthetic peptides
Synthetic peptides (SmD1, SmD3, PM1-α and Ribosomal P)
were synthesized according to the Fmoc-chemistry at the Pep-
tide Specialty Laboratories GmbH (PSL, Heidelberg, Ger-
many) as previously described [14,15,25,26]. In brief, crude
extract was purified by high-performance liquid chromatogra-
phy. The quality and purity of the peptide were assessed by
mass spectrometry and by analytical high-performance liquid
chromatography.
Anti-Sm antibody assays
Varelisa® Sm antibodies
The Varelisa® Sm assay (reference 18296; Phadia GmbH,
Freiburg, Germany) is based on a recently identified peptide
derived from the SmD3 sequence [14]. The SmD3 peptide
comprises the 16 amino acids 108–122 of SmD3 (108AARG
sDMA GRGMGRGNIF122) with an additional cysteine at the
C-terminus and a sDMA residue at position 112.
Imtec-SmD1 antibodies
The Imtec-SmD1 ELISA (catalogue number IgG TC 60029;
Human GmbH, Wiesbaden, Germany) is based on a synthetic
peptide representing the C-terminal region of SmD1 (amino
acids 83–119) first described by Riemekasten and colleagues
in 1998 [15].
RNP/Sm ELISA
The RNP/Sm ELISA (catalogue number 25011; Dr Fooke
Laboratorien GmbH, Neuss, Germany) is based on native
highly purified RNP/Sm antigen containing U1–68 kDa, U1-A,
U1-C, SmB, SmB', SmD1, SmD2, SmD3, SmE, SmF and
SmG.
Sm ELISA
The Sm ELISA (catalogue number 25010; Dr Fooke Labora-
torien GmbH) is based on native highly purified SmD antigen
from a bovine source.
Addressable laser bead assay
Microspheres embedded with laser reactive dyes (Luminex
Corporation, Austin, TX, USA) that were coupled to native Sm
antigen were part of a commercial kit (QUANTA Plex 8™;
INOVA Diagnostics Inc., San Diego, CA, USA). This profile
test also allows for the semiquantitative detection of autoanti-
bodies to chromatin, Jo-1, Rib-P, RNP, Scl-70, SS-A (Ro) and
SS-B (La). The assay was performed according to the manu-
facturer's instructions as previously described [16,27].Available online http://arthritis-research.com/content/9/4/R68
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dsDNA ELISA and native DNA indirect 
immunofluorescence
The dsDNA ELISA (catalogue number 25004; Dr Fooke Lab-
oratorien GmbH) based on a recombinant plasmid DNA was
used to measure anti-dsDNA antibodies. The assay was car-
ried out according to the manufacturer's instructions for use.
Anti-dsDNA reactivity (to native DNA) was confirmed using the
slide test with Crithidia luciliae as the substrate (Fluorescent
nDNA; ImmunoConcepts, Sacramento, CA, USA).
Competive ELISA
To analyse the populations of anti-Sm antibodies contained in
SLE sera, competitive ELISAs were carried out. Synthetic
SmD1 and SmD3 peptides were serially diluted in sample
buffer (Varelisa® kit component), resulting in peptide concen-
trations from 1.5 to 100 μg/ml. As a negative control, dsDNA
and recombinant ribosomal P2 protein were similarly diluted in
sample buffer. The binding of the anti-Sm antibodies to SmD-
coated ELISA plates was competed by a 30-minute preincu-
bation at room temperature with the respective competitor
peptide. Following the preincubation phase, the samples were
transferred onto the ELISA plates and the assays were carried
out according to the standard manufacturer's protocol of the
Varelisa® system. The percentage inhibition was calculated:
(ODwithout inhibitor - ODwith inhibitor)/ODwithout inhibitor × 100, where
OD represents the optical density.
SmD/dsDNA binding experiments
Binding of SmD-derived peptides to dsDNA was studied on
dsDNA-coated ELISA plates (Dr Fooke Laboratories). Solu-
ble, biotinylated peptides (SmD1, SmD3, PM1-α and Ribos-
omal P) were serially diluted in dilution buffer, starting at
concentrations of 1,000 ng/ml. Then 100 μl of the respective
dilutions were added to the wells of dsDNA-coated ELISA
plates and incubated for 30 minutes at room temperature.
Unbound peptides were removed by three washing cycles
with 350 μl washing buffer (kit component of the dsDNA
ELISA) per well. Peptides able to bind to dsDNA, and there-
fore immobilized in the microtitre surface, were detected by
streptavidin–horseradish peroxidase conjugate (KPL, Gaith-
ersburg, MD, USA) at a concentration of 0.5 μg/ml in combi-
nation with 3,3',5,5'-tetramethylbenzidine (kit component of
the dsDNA ELISA). The reaction was terminated with stop
solution and the optical density was measured photometrically
at 450 nm. The inhibitory effect of the SmD1 and SmD3 pep-
tides was analysed by testing an anti-dsDNA-positive sample
from a SLE patient on dsDNA-coated microtitre strips preincu-
bated with increasing concentrations of the SmD peptides as
described above. Detection of bound human anti-dsDNA anti-
bodies was according to the instructions for use of the dsDNA
ELISA (Dr Fooke Laboratories).
Bridging experiment
A serum sample with high-titre anti-dsDNA antibodies but no
anti-SmD1 (amino acids 89–119) reactivity was spiked with
increasing concentrations of dsDNA (0.4–100 μg/ml plasmid
DNA; also used in the dsDNA ELISA; Dr Fooke Laboratories)
and was incubated for 30 minutes at room temperature. The
dilution series was subsequently tested for anti-dsDNA and
anti-SmD1 reactivity in the ELISA according to the instructions
for use of the respective kit.
Statistical evaluation of results
The results obtained from the comparative study were evalu-
ated using the Analyse-it Software (version 1.62; Analyse-it
Software, Ltd, Leeds, UK). Receiver-operating characteristic
curves, positive and negative predictive values as well as the
clinical efficiency were calculated for each anti-Sm antibody
assay. The Fisher exact test and the chi-squared test were
used to analyse the statistical relevance of correlation
between two proportions.
Results
Comparison of clinical accuracy of the SmD peptide 
ELISAs
Sera from 48 unselected SLE patients and from various con-
trol samples (n = 99) were tested by two different Sm autoan-
tibody ELISAs (Varelisa®, Phadia GmbH; and Imtec-SmD1;
Human GmbH). At the cut-off value of 25 units suggested by
the manufacturer, 22/48 (45.8%) SLE sera and 22/99
(22.2%) controls were positive for anti-SmD1 antibodies (see
Table 1). In contrast, 6/48 (12.5%) SLE sera but none of the
control sera had antibodies to the SmD3-derived peptide.
To compare the ability of both assays to differentiate SLE
patients from various controls, a receiver-operating character-
istic analysis was performed. Both assays showed a compara-
ble differentiation between SLE patients and controls as
revealed by the area under the curve of the receiver-operating
characteristic analysis (see Figure 1). After adjusting the cut-
off value of the SmD1 immunoassay to 100 IU/ml to achieve
100% specificity, the same sensitivity (12.5%) was found as
in the SmD3 peptide-based ELISA (see Tables 1 and 2). At
cut-off values of 100 units for SmD1 and of 15 U/ml for SmD3,
the agreement was 100% (P < 0.0001; χ2 = 127.61).
The newly defined cut-off value (100 units) was validated in a
second, independent cohort of patients (panel III). At a cut-off
of 25 units, 16 control samples and 47 SLE samples were
positive, resulting in sensitivity of 47.0% and specificity of
84.0%. In contrast, when the new cut-off value was used, the
sensitivity and specificity for SLE were 21.0 and 1000%,
respectively (Table 1).
Technical evaluation of the SmD peptide assays
A panel of sera (n  = 65) with anti-Sm reactivity, selected
based on the test results of the Sm antibody assay contained
in the addressable laser bead assay, was tested for anti-SmD1
and anti-SmD3 antibodies by ELISA. At the cut-off value (25
units) recommended by the manufacturer, 56/65 (86.2%) seraArthritis Research & Therapy    Vol 9 No 4    Mahler et al.
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had a positive test result in the SmD1 ELISA. When the more
specific cut-off value of 100 units was used, 38/65 (58.5%)
samples showed anti-SmD1 reactivity (see Figure 2). Further,
34/65 (52.3%) of the sera tested positive for SmD3 antibod-
ies at a cut-off value of 15 units as recommended by the man-
ufacturer. When the borderline specimens (cut-off value 10 U/
ml) were included, 38/65 (58.5%) samples were positive for
anti-SmD3.
Analysis for agreement between both SmD ELISAs revealed
concordance values between 66.2% (P = 0.0025; χ2 = 9.15)
and 90.8% (P < 0.0001; χ2 = 39.37) depending on the cut-
off values (see Figure 2). The CDC international reference
serum panel was tested for autoantibodies to the SmD1 and
SmD3 peptides. Samples 1 and 5 were positive for anti-SmD1
antibodies, and sample 5 was positive for anti-SmD3 antibod-
ies. Sample 1 was borderline positive for anti-SmD3 antibod-
ies (Table 3).
Relationship between anti-SmD peptide and anti-dsDNA 
reactivity
Thirty-six out of 65 (55.4%) of the anti-Sm-positive samples
were also positive for anti-dsDNA antibodies by ELISA. Anti-
dsDNA reactivity was confirmed in 19/36 (52.8%) anti-dsDNA
ELISA-positive samples by indirect immunofluorescence on C.
luciliae substrates. Two samples were positive for anti-dsDNA
by ELISA and C. luciliae but negative for antibodies to both
SmD peptides (see Table 4).
Depending on the cut-off value, the concordance between
anti-SmD1 and anti-dsDNA reactivity ranged from 60.0% (χ2
= 1.05, P = 0.3056) to 69.2% (χ2 = 3.02, P = 0.0820), and
Table 1
Overview of the assay performance of anti-SmD1 and anti-SmD3 ELISAs determined in independent studies
Disease/control group SmD1 ELISA SmD3 ELISA
Previous studies Present study Present
study, panel I
Riemekasten 
and colleagues, 
1998 [15]
Jaekel and 
colleagues, 
2001 [20]
Panel I
(25 units)
Panel I
(100 units)
Panel III
(25 units)
Panel III
(100 units)
Mahler and 
colleagues, 
2005 [14]
Systemic lupus 
erythematosus (n)
167 111 48 48 100 100 176 48
Controls (n) 372 144 99 99 100 100 449 99
Primary Sjögren syndrome 
(n)
15 10 - - 7 7 24 -
Mixed connective tissue 
disease (n)
23 13 16 16 7 7 26 16
Rheumatoid arthritis (n) 2 8 1 0 5 05 0 2 22 2 8 6 5 0
Miscellaneous (n) 7 3 2 11 5 1 5 5 5 2 11 5
Undifferentiated connective 
tissue disease (n)
- 2 2 - -- -- -
Scleroderma (n) 2 0 1 1 1 71 7 1 81 8 2 6 1 7
Normal human donor (n) 105 50 - - 20 20 192 -
Polymyositis scleroderma 
overlap syndrome (n)
-7 1 1 1 1 6 6 - 1 1
Human immunodeficiency 
virus (n)
88 - - - 5 5 - -
Hepatitis B virus (n)2 0 - - - 5 5 - -
Hepatitis C virus (n)- - - - 5 5 3 0 -
Cytomagalovirus (n) - - - -- -2 2 -
Epstein–Barr virus (n) - - - -- -2 5 -
Sensitivity (%) 70 36 45.8 12.5 47 21 15.9 12.5
Specificity (%) 91.7 97.2 77.8 100 84 100 99.8 100Available online http://arthritis-research.com/content/9/4/R68
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Table 2
Overview of samples >25 units in the SmD1 (amino acids 83–119) ELISA
Sample ID Diagnosis SmD3 (U/ml) SmD1 (U/ml)
25413 SLE 2.8 27.50
25414 SLE 3.9 29.40
25415 SLE 2.9 26.40
25419 SLE 8.9 91.70
25423 SLE 3.7 32.50
25427 SLE 26.2 200
25429 SLE 2.4 40.6
25431 SLE 2.0 27.2
25433 SLE 179.0 200
25434 SLE 3.4 26.4
25435 SLE 6.5 41.7
25437 SLE 2.6 64.7
25441 SLE 40.4 200
25442 SLE 3.0 37.8
25443 SLE 3.8 51.9
25444 SLE 4.3 59.6
25449 SLE 4.0 78.1
25450 SLE 18.5 200
25458 SLE 7.1 79.4
25459 SLE 6.1 29.6
25461 SLE 17.0 171.0
25514 SLE 529 200
25469 RA 0.1 31.7
25470 RA 7.3 70.8
25475 RA 0.0 32.0
25479 RA 0.1 37.7
25494 RA 2.4 28.7
25495 RA 1.2 29.7
25501 RA 2.4 51.1
25510 RA 3.4 29.2
25513 PM/Scl 3.1 43.8
25516 MCTD 3.8 32.3
25517 PM/Scl 1.3 94.9
25528 Scl 3.3 30.5
25529 Overlap syndrome 4.1 63.4
25530 Overlap syndrome 7.2 57.4
25536 Scl 3.2 80.3
25537 MCTD 3.5 29.7
25539 MCTD 1.5 26.6
25540 MCTD 4.5 33.5
25544 Overlap syndrome 8.8 99.7
25552 Overlap syndrome 3.4 32.2
25553 PM/Scl 9.6 41.4
25556 MCTD 2.8 34.3
Data in bold show positive samples in the SmD3 ELISA. MCTD = mixed connective tissue disease; PM/Scl = polymyositis scleroderma overlap 
syndrome; RA = rheumatoid arthritis; Scl = scleroderma; SLE = systemic lupus erythematosusArthritis Research & Therapy    Vol 9 No 4    Mahler et al.
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the concordance between anti-SmD3 and anti-dsDNA ranged
from 53.9% (χ2 = 0.08, P = 0.7828) to 60.0% (χ2 = 1.05, P
= 0.3056).
Binding of SmD peptides to dsDNA
Binding of SmD-derived peptide to dsDNA was studied using
dsDNA-coated ELISA plates (kit component of dsDNA ELISA,
catalogue number 25004; Dr. Fooke Laboratories). Although
both SmD peptides demonstrated binding to dsDNA, the
binding of SmD1 was significantly higher than that of SmD3
(see Figure 3). No binding was observed with negative control
peptides (PM1-α and Ribosomal P).
A spiking experiment was carried out to investigate a putative
bridging effect of dsDNA on the reactivity of SmD1-negative
samples (amino acids 83–119). Increasing concentrations of
dsDNA (recombinant plasmid) showed an inhibitory effect on
the binding of anti-dsDNA antibodies to dsDNA in the ELISA.
No altered reactivity was observed in the SmD1 ELISA (see
Figure 3). When an anti-dsDNA positive serum was tested for
anti-dsDNA binding with increasing SmD1 and SmD3 peptide
concentrations, no inhibition was observed for SmD3 but
there was inhibition for SmD1 starting at a concentration of
approximately 1 μg/ml (see Figure 3).
Inhibition of anti-SmD3 reactivity with SmD1-derived 
peptide
Serum samples that have previously been identified as anti-
SmD1-positive/SmD3-positive were diluted in sample buffer
and were preincubated with increasing concentrations of
SmD1 or SmD3 peptide, and the inhibition effect was deter-
mined. After preincubation with 100 μg/ml SmD1, anti-SmD3
reactivity was significantly inhibited (60%) in one out of four
sera (data not shown).
Discussion
Since the seminal identification of anti-Sm antibodies by Tan
and Kunkel in 1966 [28], various techniques and different anti-
gens have been used for the detection of Sm antibodies.
These include double immunodiffusion, immunoblotting,
immunoprecipitation, ELISAs, and multiplex assays using
native antigens from different sources, purified or recombinant
proteins, and synthetic peptides [3,14,15,28-31]. Recom-
binant SmBB' from bacteria or insect cells and native purified
Sm antigen have also been used in kit development. Both of
these antigens contain the cross-reacting epitope PPPGM-
RPP, which is present in SmBB' and in the U1-specific RNPs
[7]. Since this epitope is frequently targeted by antibodies in
sera from patients with various autoimmune diseases, most
anti-Sm antibody assays with purified Sm or recombinant
SmBB' fail to differentiate between SLE patients and patients
with other autoimmune conditions. In a recent study we
showed that the differentiation between the closely related
autoimmune disorders SLE and MCTD can be improved by
use of the SmD3 peptide ELISA [16].
In the present study, we analysed two SmD peptide ELISAs.
Using the cut-off value recommended by the manufacturer for
human sera (25 units), we confirmed the high sensitivity (70%/
36%) and moderate specificity (91.7%/97.2%) of the SmD1
peptide-based assay as previously reported [15,20]; in our
patient cohort, we found a sensitivity of 45.8% and a specifi-
city of 77.8% (see Table 1). After receiver-operating charac-
teristic analysis, we adjusted the cut-off value to 100 units for
the SmD1 assay to achieve 100% specificity. Using this cut-
off value we found the same patients positive for anti-SmD
antibodies as with the SmD3 peptide assay, resulting in a sen-
sitivity of 12.5% and agreement between the two tests of
100% (P < 0.0001; χ2 = 127.61). It is noteworthy that anti-Sm
antibodies are considered a highly specific, but only a mod-
estly sensitive, marker for SLE. The discrepancy between this
knowledge and the reported sensitivity and specificity of the
SmD1 ELISA is critical in commercial laboratories that are not
particularly interested in rheumatic disease serology. In those
cases, general practitioners and rheumatologists often receive
positive anti-Sm test reports without knowing which anti-Sm
assay was used. With the expectation that anti-Sm is highly
SLE specific, the clinician may arrive at a wrong decision
about the diagnosis of the patient and commence inappropri-
ate therapy.
In a second independent cohort of patients (panel III), the
newly defined cut-off limit (100 units) of the SmD1 ELISA was
validated. Using the new cut-off value, the high specificity
(100.0%) and moderate sensitivity (21.0%) known for anti-Sm
antibodies were confirmed. We therefore conclude that the
Figure 1
Receiver-operating characteristic analysis of two SmD peptide-based  anti-Sm antibody assays Receiver-operating characteristic analysis of two SmD peptide-based 
anti-Sm antibody assays. The results of this comparative study were 
used to generate receiver-operating characteristic curves. The discrimi-
nation between systemic lupus erythematosus patient samples and 
control samples was similar for both SmD immunoassays.Available online http://arthritis-research.com/content/9/4/R68
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reported difference in the assay performance between the two
SmD peptide assays is mainly attributed to the different defini-
tions of the cut-off. Since our patient cohort had been previ-
ously tested for anti-Sm antibodies using purified Sm antigens
in other immunoassays, a direct comparison of the results is
possible. Commercial immunoassays based on purified native
Sm antigen demonstrate similar sensitivities of 10–12% but
lower specificities of 88–94% when compared with the SmD
peptide-based ELISAs [16]. The antigen employed in the
addressable laser bead assay is also a conventionally purified
Sm antigen comprising all Sm polypeptides, and may even
contain low concentrations of other proteins such as U1-spe-
cific RNPs. These assays therefore detect a heterogeneous
autoantibody population. In contrast, the SmD1 ELISA and the
SmD3 ELISA are based on single peptides derived from the
SmD sequence [14,15]. Consequently, when the peptide-
based assays are used, only a subset of anti-Sm antibodies is
detected.
Other Sm autoantibody specificities such as the cross-reac-
tive antibodies recognizing the MCTD-specific epitope PPPG-
MRPP, which is shared between SmBB' and U1-specific
RNPs, are not detected [7]. This explains the observation that
not all anti-Sm-positive samples from the second serum panel
Figure 2
Binding of SmD peptides to dsDNA Binding of SmD peptides to dsDNA. (a) SmD1, SmD3 and biotinylated control peptides (PM1-α and Ribosomal P) were serially diluted in dilution 
buffer (0.01–10 μg/ml) and incubated on dsDNA-coated ELISA plates. Unbound peptides were removed by washing. Immobilized peptides were 
detected by streptavidin–horseradish peroxidase conjugate in combination with 3,3',5,5'-tetramethylbenzidine substrate. The SmD1 peptide showed 
dsDNA binding starting with a concentration of approximately 40 ng/ml, and the SmD3 peptide starting with approximately 0.6 μg/ml. No dsDNA 
binding could be observed with PM1-α and Ribosomal P. (b) The inhibitory effect of the SmD1 and SmD3 peptides was analysed by testing an anti-
dsDNA-positive sample from a systemic lupus erythematosus patient on dsDNA-coated microtitre strips preincubated with increasing concentra-
tions of the SmD peptides as described above. Detection of bound human dsDNA antibodies was according to the instructions for use of the 
dsDNA ELISA (Dr Fooke Laboratories). No inhibition was observed for SmD3, but inhibition was observed for SmD1 starting at a concentration of 
approximately 1 μg/ml. OD, optical density.Arthritis Research & Therapy    Vol 9 No 4    Mahler et al.
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(n = 65) were detected by the peptide-based immunoassays.
Although anti-SmD peptide antibodies represent only a minor
subpopulation of anti-Sm antibodies, based on the high sensi-
tivity and specificity percentages as well as the observation
that anti-SmD peptide antibodies can be used to discriminate
MCTD from SLE patients, we conclude that these subpopula-
tions represent important SLE-specific antibodies [14,15]. A
mixture of RNP/Sm therefore represents an accurate tool to
screen for anti-RNP/Sm antibodies, and synthetic SmD
peptides are useful to determine the fine specificity of the
patient samples.
Since the anti-SmD peptide ELISAs showed a high degree of
concordance, we performed a competitive ELISA to study the
putative cross-reactivity. One out of four sera had a significant
decrement reactivity to SmD3 when preincubated with SmD1.
We therefore conclude that some patients produce autoanti-
bodies that cross-react with SmD1 and SmD3.
Riemkasten and colleagues reported anti-SmD reactivity in
70.0% of SLE patients and in only 8.3% of controls using a
SmD1 synthetic peptide [15]. This peptide, but not the full-
length protein, has been shown to bind dsDNA contained in
blocking reagents, which may result in the detection of anti-
dsDNA antibodies in the SmD peptide ELISA [32]. In the
present study we confirmed the dsDNA binding property of
the SmD1 peptide. This finding was further supported by the
inhibition of dsDNA binding of human anti-dsDNA antibodies
from a SLE patient. Based on this observation, one might
speculate that all sera with high titres of anti-dsDNA antibod-
ies will also be positive in the anti-SmD1 ELISA. We found
highly positive anti-dsDNA sera, however, which were nega-
tive for anti-SmD1 in the ELISA. Furthermore, no increase in
anti-SmD1 reactivity could be induced by increasing the con-
centrations of dsDNA. Coincident reactivity with dsDNA and
different Sm antigens, including full-length native antigens and
SmD-derived peptides, has been reported by several authors
[33,34]. Although correlation of anti-dsDNA and anti-SmD1
reactivity (P  = 0.0058) and of anti-dsDNA and anti-SmD3
reactivity (P < 0.001) was found in previous studies [14,15],
we could not confirm such a correlation in this study. This
might be explained by the different practices of patient selec-
tion. While the previous studies used unselected SLE patients
to establish the relationship between anti-dsDNA and anti-
SmD, in the current investigation a panel of sera was selected
based on the presence of anti-Sm antibodies. The lack of con-
cordance between anti-dsDNA and anti-SmD peptide reactiv-
ity provides additional evidence against the hypothesis that
anti-dsDNA antibodies are detected by the SmD1 (amino
acids 83–119) ELISA.
In a previous study, autoantibodies to various autoantigens in
the CDC reference sera were studied using different technol-
ogies, including the immunoblot method [35]. Only sample
AF/CDC5 showed bands corresponding to the multiple bands
of the Sm complex. All other samples were negative for anti-
Sm antibodies by various techniques [35]. There is a pressing
need, however, for the characterization of this reference panel
using newer technologies for the detection of autoantibodies.
We therefore tested the entire CDC reference sera panel for
SmD peptide reactivity. The apparent discrepant result of the
AF/CDC1 sample may be explained by low titres of anti-SmD
antibodies present in this serum. A previous study has also
reported discrepant results for this serum sample [36].
The SmD1, SmD3 and SmBB' polypeptides have recently
been shown to contain sDMA, and this constitutes a major
autoepitope within the C-terminus of SmD1 and SmD3
[14,18,37]. In one of these studies, a synthetic peptide of
SmD1 (amino acids 95–119) containing sDMA demonstrated
Table 3
Results of the Centre of Disease Control and Prevention antinuclear antibodies reference sera
Sample SmD3 SmD1 RNP/Sm ELISA SmD ELISA Autoantibody [24, 35]
1 10.3 115.6 3.0 1.9 dsDNA, ssDNA, histone, (weak) Sm
2 1.4 11.4 0.3 0.3 (weak) SS-A, SS-B
3 1.9 18.1 7.3 1.6 (weak) Sm, SS-A, SS-B
4 2.5 19.6 7.5 0.4 U1 RNP
5 >100.0 >200 7.8 6.0 Histone, Sm
6 3.1 14.5 0.5 0.3 Nucleolar
7 0.0 7.7 0.2 0.3 SS-A
8 0.1 6 0.2 0.3 Centromere
9 1.7 18 0.2 0.3 Scl-70
10 0.5 3.1 0.1 0.1 Jo-1
11 0.6 11.9 0.3 0.4 PM/Scl complex
Bold data indicate positive test result in the respective test. PM/Scl complex = polymyositis/scleroderma overlap complexAvailable online http://arthritis-research.com/content/9/4/R68
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significantly increased immunoreactivity compared with the
nonmodified peptide [18]. The new SmD3 assay is also based
on Sm peptide containing sDMA [14]. Since no study has
been published that describes the cloning, expression and
purification of SmD1/D3 or SmBB' containing sDMA, either
highly purified native SmD or synthetic Sm peptides should be
used as antigens to detect anti-Sm antibodies in the diagnosis
of SLE. Whether this modified amino acid also plays a central
role in the development of the SLE-specific B-cell immune
response to the Sm particles remains a matter of speculation.
Synthetic peptides represent ideal antigenic targets for immu-
noassays because they can easily be produced in high quality
and in quantities with low lot-to-lot variations. In 1998 Schelle-
kens and colleagues described the identification of a citrulli-
nated cyclic peptide that has become an important and
reliable marker for the diagnosis of rheumatoid arthritis [38].
Today's sophisticated epitope mapping methods will probably
lead to the identification of additional peptides, which can be
used as specific targets in diagnostic and therapeutic
approaches to patient management. This may lead to a new
scientific research area in peptide engineering with high
potential for the development of novel diagnostic and thera-
peutic products. The identification of more peptides clearly
defined by their amino acid sequence that are autoantibody
targets may accelerate progress in the international standard-
ization of the autoantibody test, an elusive goal which has
been pursued for more than 20 years.
Conclusion
In the present study we have analysed two anti-Sm antibodies
assays using synthetic SmD-derived peptides. In summary, we
Table 4
Reactivity profile of Sm-positive/dsDNA-positive sera
Sample ID ALBIAa ELISA ELISA 
dsDNA
Crithidia 
luciliae 
dsDNA
RNP Sm RNP/Sm SmD SmD1 SmD3
25480 435 396 9.2 4.8 189.1 11.2 3.9 Positive
25719 217 212 2.1 0.9 188.9 4.4 5.1 Positive
25794 487 1126 7.4 5.6 192.0 7.7 1.8 Positive
26301 167 330 6.1 1.2 183.2 >100.0 2.1 Positive
26488 126 127 1.0 0.6 17.2b 0.5b 1.8 Positive
27224 265 607 7.8 4.5 190.1 88.2 2.9 Positive
27960 165 326 7.8 5.7 182.5 23.2 3.3 Positive
28077 250 527 9.0 5.6 182.0 73.7 4.8 Positive
28242 65 102 4.0 1.6 71.2 0.7 11.1 Positive
28746 143 169 4.3 2.6 181.3 1.1 9.2 Positive
29236 98 164 5.9 1.7 182 264 6.8 Positive
29354 450 225 4.0 2.1 32.4 4.2 12.1 Positive
29659 161 132 4.9 2.2 30.1 3.3 11.6 Positive
29861 496 205 8.9 4.5 19.2b 3.3b 1.6 Positive
29907 538 520 9.3 6.2 185.0 243.0 12.2 Positive
30015 376 632 9.6 7.1 184.3 >100.0 5.0 Positive
31349 83 149 8.2 4.2 193.5 46.8 10.7 Positive
34249 348 140 8.1 4.6 >200.0 13.4 5.1 Positive
35784 494 553 8.9 5.6 >200.0 >100.0 8.3 Positive
Number/
number 
positive
19/19 19/19 18/19 16/19 14/19 9/19 19/19 19/19
aThe sample value in luminescence units(LU) can be classified as: negative, <20 LU; weak positive, 20–49 LU; moderate positive, 50–100 LU; 
strong positive, >100 LU.bdsDNA-positive/SmD-negative samples. ALBIA = Addressable laser bead assay.Arthritis Research & Therapy    Vol 9 No 4    Mahler et al.
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have found that the previously reported difference in the sen-
sitivity and specificity of both tests is caused by the cut-off def-
inition. After adjustment of the cut-off value of the SmD1
peptide assay to 100 units we found excellent agreement (P <
0.0001) between the two assays, with the same sensitivity
(12.5%) and disease specificity (100%). Moreover, we have
shown that the high binding properties of SmD1 (amino acids
83–119) to dsDNA have no significant effect on the diagnos-
tic accuracy of the SmD1 ELISA. Based on these findings, we
conclude that both SmD peptide-based assays represent a
reliable tool for the highly specific detection of anti-Sm
antibodies, and that SmD-derived peptides may become the
gold standard for the detection of anti-Sm antibodies.
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